SynthesisAnnals of the rheumatic diseases2024
Treat-to-target recommendations in giant cell arteritis and polymyalgia rheumatica.
Synthesis in Annals of the rheumatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06172361 (Efficacy and Safety of Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica), which is not on this map. Cited by 52 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica (ITTG PMR): An Open-label 52-week Randomized Controlled Trial
Who cites it
52 citing papers in PubMed, 3 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Guideline
- Evidence on treat to target strategies in polymyalgia rheumatica and giant cell arteritis: a systematic literature review.Rheumatology (Oxford, England) · 2024Pooled it
- Pooled it
- Concordance and agreement between different activity scores in polymyalgia rheumatica.RMD open · 2024Trial
- Study on the implementation of the 2015 EULAR/ACR recommendations for polymyalgia rheumatica in clinical practice.RMD open · 2026Article
- International practice patterns and beliefs concerning intravenous methylprednisolone and low-dose aspirin in giant cell arteritis.Eye (London, England) · 2026Article
- Baseline comorbidity assessment may authorize early steroid-sparing therapy in older patients with polymyalgia rheumatica.Clinical rheumatology · 2026Review
- Subcutaneous Versus Intravenous Tocilizumab in Aortitis Associated With Giant Cell Arteritis: Multicenter Study of 196 Patients.Arthritis care & research · 2026Observational
- Tackling aging and chronic disease: How space exploration and the 'chameleon effect' of pharmaceuticals can lead the way.Experimental physiology · 2026Review
- Usefulness ofClinical rheumatology · 2026Article
- Treatment strategies in giant cell arteritis and polymyalgia rheumatica: beyond glucocorticoids.Nature reviews. Rheumatology · 2026Review
- Patient-reported outcomes and disease activity in giant cell arteritis: a longitudinal registry-based study.Rheumatology (Oxford, England) · 2026Article
- Calprotectin and serum amyloid A for disease activity assessment in giant cell arteritis and polymyalgia rheumatica: results from a prospective single-centre cohort study.Rheumatology international · 2026Article
- Switching from Originator Tocilizumab to Biosimilar in Giant Cell Arteritis: Evaluation of Effectiveness and Safety in a Multicenter Cohort of 38 Patients.Drugs & aging · 2026Observational
- An aneurysm without a headache: large-vessel giant cell arteritis presenting solely as aortic aneurysm.Journal of cardiothoracic surgery · 2026Article
- Short-course prednisone and methotrexate in a cohort of patients with polymyalgia rheumatica: a potential therapeutic approach.BMC rheumatology · 2026Article
- Treatment and evolution of 134 patients with aortitis and periaortitis: experience of a third-level university hospital.Internal and emergency medicine · 2026Observational
- Large vessel vasculitis combined with inflammatory bowel disease: epidemiology, shared pathogenesis, and therapeutic advances.Frontiers in immunology · 2026Review
- Measurement of the impact of giant cell arteritis and treatment with glucocorticoids on health-related quality of life.Therapeutic advances in musculoskeletal disease · 2026Review
- Patient experiences of PMR: a qualitative narrative literature review.Rheumatology advances in practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 20 institutions in 10 countries.
Funding
Abstract
objectivesTo develop treat-to-target (T2T) recommendations in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR).
methodsA systematic literature review was conducted to retrieve data on treatment targets and outcomes in GCA/PMR as well as to identify the evidence for the effectiveness of a T2T-based management approach in these diseases. Based on evidence and expert opinion, the task force (29 participants from 10 countries consisting of physicians, a healthcare professional and a patient) developed recommendations, with consensus obtained through voting. The final level of agreement was provided anonymously.
resultsFive overarching principles and six-specific recommendations were formulated. Management of GCA and PMR should be based on shared decisions between patient and physician recognising the need for urgent treatment of GCA to avoid ischaemic complications, and it should aim at maximising health-related quality of life in both diseases. The treatment targets are achievement and maintenance of remission, as well as prevention of tissue ischaemia and vascular damage. Comorbidities need to be considered when assessing disease activity and selecting treatment.
conclusionThese are the first T2T recommendations for GCA and PMR. Treatment targets, as well as strategies to assess, achieve and maintain these targets have been defined. The research agenda highlights the gaps in evidence and the need for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.